Comparative Pharmacology
Head-to-head clinical analysis: NAFCILLIN SODIUM versus PENBRITIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAFCILLIN SODIUM versus PENBRITIN.
NAFCILLIN SODIUM vs PENBRITIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nafcillin exerts bactericidal activity by inhibiting bacterial cell wall synthesis via binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamases.
Penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and preventing peptidoglycan cross-linking, leading to cell lysis.
1-2 g IV every 4 hours; or 1-2 g IM every 4-6 hours.
250-500 mg orally every 6 hours; 500 mg to 2 g intramuscularly or intravenously every 4-6 hours.
None Documented
None Documented
Approximately 0.5 hour (30 minutes) in adults with normal renal function; prolonged to 1-2 hours in neonates or severe renal impairment. Clinically relevant for dosing every 4-6 hours.
0.5-1 hour in normal renal function; extended to 2-6 hours in renal impairment. Hemodialysis shortens half-life.
Primarily renal (30-40% unchanged) and hepatic/biliary elimination. Approximately 10-15% excreted in bile via feces.
Renal: ~75-90% unchanged via glomerular filtration and tubular secretion. Biliary: ~10% in feces. Minor hepatic metabolism to penicilloic acid.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic